Novocure (NVCR) Stock Forecast & Price Target

NovoCure is supported by accelerating commercial execution, with 2Q26 revenue of $183.6M growing 5.5% QoQ and beating consensus, while management raised 2026 net revenue guidance to $710-$725M and lifted adjusted EBITDA guidance to $0-$15M. The bullish case is strengthened by broad-based demand across all marketed therapies, including a record number of active GBM patients in the US, stronger-than-expected Optune Lua uptake in Japan, and favorable early Optune Pax feedback in pancreatic cancer. Its pipeline and expanding labels add further upside, as METIS could support a 4th FDA approval in 4Q26, while ongoing trial progress and $440.6M in cash provide financial flexibility to fund growth and new launches.

NovoCure is facing a more difficult fundamental setup as the TRIDENT miss reduced perceived long-term growth potential in GBM, where TTFields is already widely used in newly diagnosed disease, limiting incremental upside. The outlook is further pressured by reliance on Optune adoption and clinical execution across multiple indications, with downside tied to poorer-than-expected sales, competitive pressure, regulatory setbacks, safety signals, or studies that fail to achieve statistical significance. Even with a DCF framework that assumes meaningful success in Optune, 2L NSCLC, and pancreatic cancer, the company still carries substantial binary clinical risk and a lowered estimate profile, supporting a cautious stance.